Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany.
Luise Heinrich, Thomas Birkner, Susanne Abraham, Sascha Gerdes, Tatjana Honstein, Sigrid Müller, Matthias Augustin, Inken Harder, Thomas Schaefer, Andreas Pinter, Anne Bong, Jutta Ramaker-Brunke, Tilo Biedermann, Michael Sticherling, Hannah Gorriahn-Maiterth
Abstract
Open AccessThe TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date. We report the Harmonising Outcome Measures for Eczema (HOME) core outcome set. The Eczema Area Severity Index (EASI) 75 and EASI 90 response rates for patients on treatment at month 24 were 78.8% and 51.2%, respectively.